evidence: Multiple studies provide data that hydroxychloroquine (brand name: Plaquenil) does not provide a medical benefit for hospitalized patients with COVID-19. Hydroxychloroquine, an FDA-approved prescription drug used for malaria, rheumatoid arthritis and lupus erythematosus, has been suggested as a possible treatment or preventive for COVID-19 based on demonstrated antiviral or immune system activity. [...] Accessed August 12, 2020 at https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-management-in-hospitalized-adults - Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020;10. doi:10.1056/NEJMoa2019014 - Skipper C, Pastick K, Engen N. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. A Randomized Trial. Ann Intern Med. July 16, 2020. Accessed August 13, 2020 at doi.org/10.7326/M20-4207 - Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403. doi:10.1016/j.ijid.2020.06.099 - Boulware D, Pullen M, Bangdiwala A, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 N Engl J Med 2020; 383:517-525 DOI: 10.1056/NEJMoa2016638 - Veklury (remdesivir) [product information]. Foster City, CA, Gilead Sciences. Accessed Oct. 23, 2020 at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf - FDA Approves First Treatment for COVID-19. US Food and Drug Administration (FDA). Accessed Oct. 23, 2020 at https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 - The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. July 17, 2020. N Engl J Med. Accessed Oct. 23, 2020 at DOI: 10.1056/NEJMoa2021436.